pdf   xlsx method abbreviations

renal cell cancer (RCC), atezolizumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 1.19 [0.82, 1.72]< 10%1 study (1/-)17.7 %NAnot evaluable important-
objective responses (ORR) 0.80 [0.43, 1.48]> 10%1 study (1/-)23.6 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.51 [0.05, 5.72]< 10%1 study (1/-)70.6 %NAnot evaluable non important-
AE (grade 3-4) 0.30 [0.17, 0.53]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
AE leading to death (grade 5) 0.97 [0.13, 7.02]< 10%1 study (1/-)51.2 %NAnot evaluable non important-
TRAE (any grade) 0.21 [0.07, 0.65]< 10%1 study (1/-)99.7 %NAnot evaluable non important-
TRAE (grade 3-4) 0.15 [0.08, 0.29]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.24 [0.01, 5.37]< 10%1 study (1/-)81.3 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Colitis TRAE (grade 3-4) 0.98 [0.02, 49.90]< 10%1 study (1/-)50.4 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 0.98 [0.02, 49.90]< 10%1 study (1/-)50.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons